Vector-Free Intra-Airway In Vivo Epigenetic Editing: A Breakthrough in Gene Therapy

Strategic Insights -

Researchers from Rhode Island Hospital and Brown University's Medical School have published a groundbreaking study on vector-free, targeted promoter demethylation in vivo, paving the way for novel gene therapy approaches. The study, published in Trends in Biotechnology, demonstrates the potential of using recombinant, gene-targeted epigenetic editor proteins to directly target and demethylate specific DNA promoters in the lung cells of mice. This approach eliminates the need for transgenesis, vectors, or packaging tools, making it a more translational method for human applications.

Key Takeaways:

  • The study describes the design of recombinant, gene-targeted epigenetic editor proteins that can be directly taken up by mouse lung cells in vivo without the need for transgenesis, vectors, or packaging tools.
  • The proteins use either dCas9 or artificial zinc finger domains to target specific promoters, and thymine-DNA-glycosylase (TDG) and ten-eleven translocation proteins (Tet) catalytic domains to mediate specific demethylation.
  • Results demonstrate the intranuclear arrival of epigenetic editors in vitro and in mice, local DNA demethylation, and resulting highly gene-specific derepression of the transcriptional response, which confers sensitivity to interferon (IFN) stimulation.
  • This study provides proof of principle for vector-free, targeted promoter demethylation in vivo, offering a promising strategy for experimental and therapeutic regulation of gene expression.
  • Mohankumar Ramar, Naohiro Yano, David J. Gregory, and Alexey V. Fedulov contributed to this research, with Ramar serving as the primary contact.
  • The study has significant implications for the development of novel gene therapy approaches that can directly target and modify specific genes in the lungs of individuals with genetic disorders.

Statistics:

  • The study was published in Trends in Biotechnology, with a volume of 43(9) and page numbers 2251-2275.
  • The journal Trends in Biotechnology is published by Cell Press and can be contacted at 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA.
  • The study was peer-reviewed and demonstrated a highly gene-specific derepression of the transcriptional response, with a resulting sensitivity to interferon (IFN) stimulation.
  • The results provide proof of principle for vector-free, targeted promoter demethylation in vivo, making it a promising strategy for experimental and therapeutic regulation of gene expression.

Sources:

  • Vector-free intra-airway in vivo epigenetic editing. Trends in Biotechnology, 2025;43(9):2251-2275.